BRAD is the Newest Human Peptide for Beta Cell Generation


BRAD/Banta™ causes regeneration of new insulin-producing beta cells in the pancreas by binding directly to ductal progenitor cells.

BRAD is among a new class of regeneration (Reg gene) therapies that have been shown in human clinical trials among Type 1 patients to increase one’s own insulin by 27% within 8 weeks of therapy